Cardinal Health Stock News

DUBLIN, Ohio , Feb. 3, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on April 15, 2025, to shareholders of record at the close of business on April 1, 2025.

Cardinal Health, Inc. (NYSE:CAH ) Q2 2025 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants John Stansel - JPMorgan Erin Wright - Morgan Stanley Allen Lutz - Bank of America Elizabeth Anderson - Evercore Michael Cherny - L...

Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.

Revenue decreased 4% to $55.3 billion; revenue increased 16% excluding the impact of the previously communicated large customer contract expiration GAAP 1 operating earnings were $549 million; GAAP diluted EPS was $1.65 Non-GAAP operating earnings increased 9% to $635 million, driven by the Pharmaceutical and Specialty Solutions segment; non-GAAP diluted EPS increased 2% to $1.93 Fiscal year 20...

Cardinal Health, Inc. (NYSE:CAH ) J.P. Morgan Healthcare Conference January 14, 2025 12:00 PM ET Company Participants Aaron Alt - CFO Jason Hollar - CEO Conference Call Participants Lisa Gill - JPMorgan Lisa Gill Good morning.

New facility will be outfitted with latest robotics and automation technologies DUBLIN, Ohio , Jan. 14, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced construction is underway on a new distribution center in Fort Worth, Texas, which will support its at-Home Solutions business, a leading medical supplies provider that serves more than 5 million patients annually in the United States....

Cardinal Health said on Tuesday it expects annual profit to be at the higher end of its previous forecast range, primarily driven by strong demand for costly specialty medicines and branded drugs at its pharmaceuticals unit.

With all of the major indices making solid moves higher in 2024, we were very interested to see what the top prognosticators across Wall Street think is in store for 2025 as we start the second quarter of the new century.